NDANASALSPRAY
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
REZENOPY (naloxone hcl) by Hikma is sites. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZENOPY is a naloxone hydrochloride nasal spray approved by the FDA in April 2024 for rapid reversal of opioid overdose effects including respiratory depression, sedation, and hypotension. It acts as a competitive opioid antagonist at mu receptors, displacing opioids and rapidly restoring normal respiratory function. The nasal spray formulation enables quick, non-invasive administration in emergency settings.
Growth14.3 years to LOE
Early-stage growth product with potential for rapid market adoption in emergency medicine and overdose reversal; team building and market development activities are likely.
Mechanism of Action
sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REZENOPY represents a growth-stage commercial opportunity with minimal competitive threat and strong patent protection, making it attractive for brand-building, field sales, and market access roles. The emergency care setting and overdose reversal indication offer meaningful healthcare impact and potential for rapid market adoption among first responders and healthcare providers.
Brand Manager
Worked on REZENOPY at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.